Last reviewed · How we verify
NCT04863690: MuseSleep
Assessing the Effects of the Muse Sleep Intervention on Sleep
NA trial testing Meditation in Mediation in 150 participants. Completed in 1 December 2022.
1 May 2022
Quick facts
| Lead sponsor | Western University, Canada |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 150 |
| Start date | 1 May 2021 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Meditation
- Digital Coaching
- Digital Coaching plus Human Coaching
Conditions studied
Sponsor
Western University, Canada
Who can join
Adults 18 to 100, any sex, with Mediation or Coaching. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, we will examine whether use of the Sleep Intervention protocol marketed by Interaxon (the 'Muse'), leads to improvements in sleep quality (e.g. decreased latency to sleep, improved sleep duration), as well as knock-on improvements on measures of mindfulness, improvement in quality of life scores, reduction in perceived stress levels, anxiety, improvements in cognitive performance, improvement in markers relevant for safety, and increased success in the workplace in healthy participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04863690
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Meditation
Trials testing the same drug.
- NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
- NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
- NCT07310992 — Effect of Meditation as an Adjunct to Cardiac Rehabilitation · NA · not yet recruiting
- NCT07176013 — Immersive Virtual Reality Meditation in Voice Therapy · NA · enrolling by invitation
- NCT06866288 — Belongingness in Nursing Through Mindfulness - BEING Mindful: A Pilot Study · NA · completed
Other Western University, Canada trials
Trials by the same sponsor.
- NCT07485062 — Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes · Phase 4 · not yet recruiting
- NCT07372755 — Feasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders · not yet recruiting
- NCT07302308 — Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders. · not yet recruiting
- NCT04323423 — The DURATION Study: reDUcing sedentaRy behAviour to Maintain cogniTIve functiON. · NA · withdrawn
- NCT07204301 — Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Pat · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04863690 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western University, Canada
- Last refreshed: 25 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04863690.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing